Please login to the form below

Not currently logged in

Another $2m donated to further neurodegenerative commitment

Research funders build on global initiative for brain deteriorating diseases

alzheimersFunders in the US, Canada and the UK have offered nearly $2m to advance research into progressive neurodegenerative diseases as part of an expanded partnership.

The Biomarkers Across Neurodegenerative Diseases (BAND) programme is a joint initiative of the Alzheimer's Association and The Michael J. Fox Foundation for Parkinson's Research in the US, the Weston Brain Institute in Canada and Alzheimer's Research UK, which joins as the programme makes a second round of research grant awards available.

Nearly $2m (£1.3m) is to be offered for projects investigating the connection in the biology and clinical symptoms of Alzheimer's, Parkinson's, frontotemporal dementia (FTD) and other brain deteriorating diseases.

Dr Simon Ridley, head of Alzheimer's Research UK, commented: “Alzheimer's Research UK is pleased to be joining this initiative, which we hope provides a vital new understanding of Alzheimer's and other brain diseases. 

“With growing numbers of people affected by neurodegenerative diseases, investment in research is crucial if we are to transform people's lives. Charities have an important role to play in this fight and we are proud to be part of this collaborative effort to boost global research.”

Projects supported by BAND will compare data across the aforementioned diseases including generic information, brain changes detected through imaging tolls such as MRI scans, and measure relevant symptoms including memory problems or physical tremors. 

Mark Fraser, senior VP of research programmes at The Michael J. Fox Foundation, added: “A collaboration such as BAND promotes research efficiency. Expanding investigation beyond a single diagnosis opens the door to new discoveries, which can only benefit drug development and thereby the millions of patients who need new therapies.”

Alzheimer's Research UK joining to the BAND programme comes just weeks after the charity announced the formation of a £30m drug discovery alliance with three universities in the UK.

Article by
Kirstie Pickering

9th March 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...